Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study
22 Febrero 2024 - 7:00AM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced it has
completed selection of Principal Investigators for its
proof-of-concept human clinical study evaluating the use of
transvascular RF ablation for the treatment of pancreatic cancer
pain. Additionally, the Principal Investigators have successfully
completed training for the PoC study.
“We are building important momentum with the
advancement of our PoC human clinical study. We worked diligently
to identify and secure our Principal Investigators for the study
and have completed the training for this first study ever to
evaluate RF ablation in a transvascular approach. Our lead
investigator performing the procedure is not only trained in
interventional radiology, but he is also a cardiac surgeon. With
these critical steps now completed, we remain on track to commence
patient enrollment this quarter,” commented Lori Bisson, Chief
Executive Officer of Autonomix.
The primary objective of the proof-of-concept
human clinical study is to successfully ablate relevant somatic
nerves and mitigate pain in patients with pancreatic cancer pain
utilizing RF ablation in a transvascular approach to the nerves in
the region. Twenty (20) subjects will be enrolled at one clinical
trial site for the study. Confirmation of suitability will be
affirmed by the primary oncology service caring for the patients.
Up to 5 additional patients will be included and treated according
to protocol to ensure the physician’s familiarity with the
procedure. However, they will not be included in the analysis of
the study objectives. Enrollment is expected to be completed before
the end of 2024.
Expected Upcoming
Milestones
- Q1 CY2024: Commence enrollment in
PoC human clinical study evaluating proprietary ablation technology
for treatment of pancreatic cancer pain
- 2024: Complete ablation device
design intended for clinical use
- 2025: Complete development of
ablation system and catheter in preparation for human pivotal
trial
- 2025: Launch combined sensing /
ablation clinical trial
- 2026: De novo submission
- 2027: Seek FDA clearance
The Company’s catheter-based technology is being
developed to do two things: sense neural signals associated with
pain or disease and precisely target those nerves for treatment.
Autonomix believes this technology is a better alternative to the
current approaches commonly used today, where doctors either rely
on systemic drugs like opioids that lose effectiveness and have
unwanted side effects or treat suspected areas blindly in hopes of
hitting the right nerves, an approach that is often inaccurate and
can miss the target and even cause collateral damage to surrounding
parts of the body.
The Company is initially developing its
technology to address pancreatic cancer-related pain. Current
approaches, primarily relying on opioids or invasive ethanol
injections, can provide only limited relief and may lead to risky
side effects. For more information about the Company’s technology,
please visit autonomix.com.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain, a condition that can cause debilitating
pain and needs an effective solution. However, our technology
constitutes a platform with the potential to address dozens of
indications, including in cardiology, renal denervation and chronic
pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the timing of the completion of
patient enrollment in the study and the Company’s ability to
successfully meet the milestones set forth in this press release on
a timely basis, if at all. Such forward-looking statements can be
identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’
‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’
‘expects,’ ‘plans,’ and ‘proposes.’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the offering statement
filed with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media Contact
JTC Team, LLCJenene Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Autonomix Medical (NASDAQ:AMIX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024